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1Department of Materials Science and Engineering, The Johns Hopkins University, Baltimore, MarylandABSTRACT Thanatophoric dysplasia type I (TDI) is a lethal human skeletal growth disorder with a prevalence of 1 in 20,000 to
1 in 50,000 births. TDI is known to arise because of five different mutations, all involving the substitution of an amino acid with a
cysteine in fibroblast growth factor receptor 3 (FGFR3). Cysteine mutations in receptor tyrosine kinases (RTKs) have been
previously proposed to induce constitutive dimerization in the absence of ligand, leading to receptor overactivation. However,
their effect on RTK dimer stability has never been measured experimentally. In this study, we characterize the effect of three
TDI mutations, Arg248Cys, Ser249Cys, and Tyr373Cys, on FGFR3 dimerization in mammalian membranes, in the absence
of ligand. We demonstrate that the mutations lead to surprisingly modest dimer stabilization and to structural perturbations of
the dimers, challenging the current understanding of the molecular interactions that underlie TDI.INTRODUCTIONThanatophoric dysplasia type I (TDI) is a lethal human skel-
etal growth disorder with a prevalence of 1 in 20,000 to 1 in
50,000 births. It is one of the most severe of the skeletal dys-
plasias and typically leads to neonatal death (1–3). Typical
features of the TDI phenotype include shortened limbs
with bowed femurs and cloverleaf skull deformities.
TDI is known to arise because of five different mutations,
all involving the substitution of an amino acid with a cysteine
in fibroblast growth factor receptor 3 (FGFR3): Arg248Cys,
Ser249Cys, Gly370Cys, Ser371Cys, and Tyr373Cys (4–6).
Of these, Arg248Cys and Tyr373Cys account for 60% to
80% of all cases of TDI. These cysteine mutations have
been shown to increase the phosphorylation and activation
of the receptor in the absence of ligand (7,8), increase down-
stream extracellular signal-related kinase signaling (9), and
increase BaF3 cell proliferation (10). Themutations compro-
mise the downregulation of activated FGFR3 dimers in the
plasma membrane (11) and increase retention of FGFR3 di-
mers in the endoplasmic reticulum (12). Furthermore, it has
been shown that overactivation of FGFR3 leads to the inhibi-
tion of chondrocyte proliferation during development, which
impedes bone growth (13,14).
FGFR3 is a receptor tyrosine kinase (RTK) that consists
of an extracellular (EC) domain involved in ligand binding,
a single-pass transmembrane (TM) domain, and an intra-
cellular tyrosine kinase domain. Like all RTKs, FGFR3
functions via a lateral dimerization process that brings the
kinase domains into close proximity so that they can phos-
phorylate and activate each other (5,15–17).
Mutations to cysteine residues in RTKs have been pro-
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0006-3495/15/01/0272/7 $2.00bonds, thereby inducing constitive dimerization and activa-
tion (7,18–20). However, the effect of the mutations on un-
liganded RTK dimer stability has never been characterized
in quantitative terms. In this study, we characterize the ef-
fect of three TDI mutations, Arg248Cys, Ser249Cys, and
Tyr373Cys, on the stability and the structure of FGFR3
dimers. We accomplish this by using a Fo¨rster Resonance
Energy Transfer (FRET)–based technique (21,22) that
yields dimerization free energies of glycosylated RTKs
and reports on structural differences between RTK dimers.
Measurements are performed in plasma membrane vesicles
derived from Chinese hamster ovary (CHO) cells with the
use of a novel osmotic stress vesiculation method (23).
We find that the three TDI mutations cause a modest stabi-
lization of the FGFR3 dimer. We also observe modest struc-
tural perturbations in the FGFR3 dimer because of the
mutations.MATERIALS AND METHODS
Plasmid constructs
In the FGFR3 construct used for these experiments, the catalytic domain
was substituted with a fluorescent protein to enable FRET-based detection
of receptor dimerization. The construct consists of the extracellular (EC)
and transmembrane (TM) domains of FGFR3 followed by a flexible 15
amino acid linker, (GGS)5, and either eYFP or mCherry. The DNA encod-
ing for this construct was placed between the HindIII and XbaI multiple
cloning sites of the pcDNA3.1(þ) vector (Invitrogen, Carlsbad, CA) (22).
Constructs containing each of the TDI mutations were generated from these
two initial wild-type constructs using mutagenesis.Mutagenesis
Each of the TDI constructs was created by introducing a mutation into
the wild-type FGFR3 constructs containing eYFP and mCherry. This
was accomplished using the QuikChange XL II Mutagenesis Kit (Agilenthttp://dx.doi.org/10.1016/j.bpj.2014.11.3460
FIGURE 1 Typical plasma membrane–derived vesicles with wild-type
FGFR3. Scale bar ¼ 20 mm. To see this figure in color, go online.
TDI Mutations and FGFR3 Dimerization 273Technologies, Santa Clara, CA). Primers were designed according to
the manufacturer’s instructions and ordered from Invitrogen. For the
Arg248Cys constructs, the following primers were used to create the
742C to T nucleotide transition: forward 50 - GCTGGACGTGCTGGAG
TGCTCCCCGCACCGGC - 30 and reverse 30 - CGACCTGCACGACCTC
ACGAGGGGCGTGGCCG - 50. For the Ser249Cys constructs, the 746C to
G nucleotide transition was created using the forward primer 50 - CGTG
CTGGAGCGCTGCCCGCACCGGCCCATCC - 30 and the reverse primer
30 - GCACGACCTCGCGACGGGCGTGGCCGGGTAGG - 50. For the
Tyr373Cys constructs, the 1118A to G nucleotide transition was generated
using the forward and reverse primers 50 - CGAGGCGGGCAGTG
TGTGTGCAGGCATCCTCAGC - 30 and 30 - GCTCCGCCCGTCACACA
CACGTCCGTAGGAGTCG - 50. Following mutagenesis, all constructs
were sequenced (Genewiz, Fredrick, MD) to ensure no other variations
were introduced. All plasmids were amplified using DH5a cells.Cell culture conditions
CHO cells were cultured in Dulbecco’s modified Eagle medium supple-
mented with 10% fetal bovine serum (HyClone, Logan, UT), 1 mM nones-
sential amino acids, 1.8 g/L D-glucose, and 1.5 g/L sodium bicarbonate. The
cells were cultured in T25 tissue culture flasks and passed every other day.Transfection and vesiculation
CHO cells were seeded into a six-well plate at a density of 2 to 4 104 cells
per well. Cells were grown for 24 h before transfection. Transfection
was carried out using FuGENE HD (Roche Applied Sciences, Basel,
Switzerland) according to the manufacturers’ protocol. Plasmids encoding
for the FGFR3 constructs labeled with the donor (eYFP) and with the
acceptor (mCherry) were transfected in a 1:3 ratio. After transfection, cells
were grown for an additional 24 h before vesiculation.
Vesicles were produced from the transfected CHO cells using an osmotic
stress method (23). The vesiculation buffer solution consisted of 200 mM
NaCl, 5 mM KCl, 0.5 mM MgCl2, 0.75 mM CaCl2, and 100 mM bicine.
The pH of the solution was set to 8.5 using 1 M HCl and 5 M NaOH stock
solutions. The first step in the vesiculation process was to incubate each
well of CHO cells in 1 mL of 30% PBS for 1 min at room temperature. After
this step, 1 mL of the vesiculation buffer was added to each well, and the
samples were incubated for 13 h at 37C. Then, vesicles were transferred
into Lab-Tek II four-chambered coverglass slides (Nunc, Penfield, NY)
for image acquisition. To determine the pH of the buffer during the imaging
experiments, the vesicle solution was filtered and the pH was measured
using a micro conductivity sensor (Mettler Toledo, Columbus, OH). The
pH of the buffer after vesiculation was consistently measured as 8.Image acquisition and analysis
All images were acquired using a Nikon (Melville, NY) Eclipse confocal
laser scanning microscope and a 60 water immersion objective. Each
vesicle was imaged in three different scans. The donor scan utilized excita-
tion of eYFP at 488 nm and emission collection between 500 and 530 nm
(Fig. 1 shows examples of donor scans). In the FRET scan, eYFP was
excited at 488 nm, and emission was collected in the 565 to 615 nm range.
The acceptor scan utilized excitation of mCherry at 543 nm and collection
of emission >650 nm using a long pass filter. The gains for the donor,
FRET, and acceptor scans were set to 6.50, 7.00, and 7.25, respectively.
The field of view for all images was set to 100 by 100 mm and images
were acquired at a resolution of 512  512 with a pixel dwell time of
1.68 ms to minimize photobleaching.
The images were processed using a MATLAB (MathWorks, Natick, MA)
program developed in the lab, as described previously (21). A Gaussian
function was fitted to the fluorescence intensity across the membrane aftercorrecting for background fluorescence (21) (see Supporting Material). The
integrals of these Gaussian functions gave the fluorescence intensities per
vesicle, IDonor, IFRET, and IAcceptor for the donor, FRET, and acceptor scans,
respectively.
Fluorescent protein solutions of known concentration were prepared as
described in an earlier study (24) and imaged in the donor and acceptor
scans. These solution standards were used to determine the linear relation-
ship between fluorescence intensities and fluorescent protein concentrations
for both eYFP and mCherry (25). This information was used to determine
the concentration of acceptors and donors in each vesicle. First, the acceptor




where IAcceptor is the integrated intensity of the membrane in the acceptor
scan and iA is the slope of the fluorescence intensity versus concentration
plot for the acceptor standard solutions. Next, the sensitized acceptor emis-
sion, ISEN, was calculated. To do this, the bleed-through coefficients, bD
and bA, for the donor and acceptor were determined using the solution
standards. The sensitized acceptor emission, ISEN, for each vesicle was
determined as follows (21)
ISEN ¼ IFRET  bAIA  bDID: (2)
The actual donor concentration (CD,Corrected) per vesicle was calculated as
follows (21)





The gauge factor,GF, in Eq. 3 is an experimentally determined constant that
relates the sensitized emission to donor quenching and depends on both
the instrument and the FRET pair. This constant was measured by imaging
vesicles containing a soluble construct of eYFP linked to mCherry in a 1:1
ratio as described in an earlier study (25).
The FRET efficiency for each vesicle was calculated according to the
following:
E ¼ 1 ID
ID;Corrected
: (4)
The FRET efficiency observed in each vesicle is known to have two
different contributions (1): specific FRET because of the presence of
FGFR3 dimers and (2) proximity FRET because of the random approach
of donors and acceptors in the membrane (21,26,27). The proximity
FRET contribution, shown as a solid black line in Fig. 2, arises because
of the confinement of the fluorophores to the two-dimensional (2D) mem-
brane. The proximity FRET contribution, (calculated as discussed in detailBiophysical Journal 108(2) 272–278
FIGURE 2 FRET efficiency versus acceptor concentration: wild-type
FGFR3 (open blue diamonds), Arg248Cys FGFR3 (red squares),
Ser249Cys FGFR3 (green triangles), and Tyr373Cys FGFR3 (purple cir-
cles). Each data point represents a single vesicle and has a distinct donor
concentration. The solid black line accounts for the proximity FRET,
known to occur because of the random approach of donors and acceptors
within distances of 100 A˚ in the membrane. The FRET data lie above
this proximity line, indicating specific FGFR3 interactions. The FRET effi-
ciencies measured for the mutant receptors are higher than those measured
for the wild-type receptors, indicating that the TDI mutations have an effect
on FGFR3 dimerization. To see this figure in color, go online.
274 Del Piccolo et al.in (27)), was subtracted from the measured FRET efficiency to determine
the FRET due to dimerization
ED ¼ E Eproximity: (5)
The fraction of receptors that exist in dimers, fD, was calculated in each






where xA is the fraction of acceptors in a given vesicle, and Ẽ is the so-called
intrinsic FRET efficiency. The intrinsic FRET is a structural parameter that
depends on the separation and orientation of the donor and the acceptor in a
dimer. The dependence of the intrinsic FRET, Ẽ, on the distance between








where d is the distance between the acceptor and the donor in the dimer, and
Ro is the Fo¨rster radius of the FRET pair (21). For eYFP and mCherry, Ro is
53 A˚, measured by us assuming free fluorophore rotation. The assumption
of free rotation of the fluorescent proteins in our experiments is justified,
because they are attached to the receptors via long flexible linkers (28).
Since Ẽ is generally unknown (because the structures of the wild-type
and the mutants are unknown and may be different), the quantity measured





Equation 8 assumes that the probabilities for the formation of donor-donor,
donor-acceptor, acceptor-donor, and acceptor-acceptor dimers are the same.
This is a reasonable assumption because we use monomeric fluorescent
proteins that are not expected to affect dimerization.
The two-state thermodynamic model describing equilibrium between
monomers and dimers is given by the following reaction scheme:
M þM4K D (9)
Based on this simple dimerization model, the dimeric fraction can be ex-








ð1þ 8TKÞ1=2  1

: (10)
Predictions for dimeric fractions, generated by Eq. 10, were fitted to the
experimental data measured according to Eq. 8, while varying the two
unknown parameters, namely the dimerization constant, K, and the intrinsic
FRET, Ẽ. A least-square two parameter fitting procedure for K and Ẽ was
performed for each data set using MATLAB.
The Gibbs free energy of dimerization is calculated for each construct
using the following equation
DG0 ¼ RT lnK; (11)
with a standard state defined as 1 nm2/receptor (21).
Finally, the intrinsic FRET value, obtained in the two-parameter fit,
allows us to calculate the distance between the fluorescent proteins in
each of the different FGFR3 dimer structures, according to Eq. 7.Statistical analysis
A c2 analysis was used to compare the wild-type data set with each of the
TDI mutant data sets. In particular, we tested the null hypothesis that the
data sets being compared were not different. For each data set, the results
were averaged within bins of 5  104 receptors/nm2. These bins were








where i is the number of bins, and avgwt,i and avgmut,i are the average values
in the wild-type and mutant bins, respectively. The standard error for each
bin, SEi, is defined as follows:
SEi ¼
ðSEwt;iÞ2 þ ðSEmut;iÞ21=2; (13)
where SEwt,i and SEmut,i are the standard errors in the wild-type and mutant
bins, respectively. Finally, using these ci
2 values and df, the degrees of
freedom, equal to the number of bins minus one, we calculated the reduced








We also determined p-values using a c2 table (29). The cutoff for signifi-
cance is p < 0.05.
TDI Mutations and FGFR3 Dimerization 275Additional statistical analysis was used to compare the K and Ẽ param-
eters determined for the wild-type with those determined for each of the
mutants. We tested the null hypothesis that the average values were not
different from each other. We used GraphPad Prism (La Jolla, CA) to
analyze the data with analysis of variance (ANOVA) and to calculate


























FIGURE 3 Donor and acceptor concentrations in each individual vesicle:
wild-type FGFR3 (open blue diamonds), Arg248Cys FGFR3 (red squares),
Ser249Cys FGFR3 (green triangles), and Tyr373Cys FGFR3 (purple
circles). To see this figure in color, go onlineRESULTS
In the experiments reported in this study, we characterized
the unliganded dimerization of wild-type FGFR3 and three
TDI mutants in plasma membrane–derived vesicles. Exper-
iments were performed with receptors in which the intracel-
lular domains were substituted with fluorescent proteins
(eYFP or mCherry) to allow for FRET detection.
The fluorescent proteins were attached to the TM do-
mains via flexible (GGS)5 linkers, as described in Materials
and Methods. The (GGS)5 linker has been shown to be un-
structured and behave like a random coil with an apparent
radius of ~45 A˚ (28), when fused between two proteins. It
has been further shown that models that assume free rota-
tions of the fluorescent proteins attached to the two sides
of the linker correctly predict the measured FRET efficiency
(28). Based on these studies, it can be safely assumed that
the fluorophores are rotating freely, and the distance be-
tween the fluorophores depends only on the points of attach-
ment of the linkers to the protein, in this case the distance
between the C-termini of the TM domains in the dimer.
To obtain vesicles containing FGFR3, we first co-trans-
fected CHO cells with plasmids encoding for either the
wild-type or the TDI mutants linked to eYFP and mCherry.
Since the receptors are produced in CHO cells, they undergo
all required posttranslational modifications, including full
glycosylation. Following transfection, plasma membrane–
derived vesicles were produced from the CHO cells using
an osmotic stress method (23). Such vesicles do not have
the actin cytoskeleton (30–32), which is known to play an
important role in maintaining the lateral heterogeneity
of biological membranes. Consistent with this, we invari-
ably observe homogeneous distribution of fluorescence
throughout the vesicle membrane (21,23).
The vesicles were transferred to chambered coverglass
slides for image acquisition. Theywere imaged using aNikon
Eclipse C1 laser scanning confocal microscope. Each vesicle
was imaged using three separate scans: a donor scan, a FRET
scan, and an acceptor scan, as described in previous publica-
tions (25,33–36). Following image acquisition, vesicles were
processed using an in-house MATLAB script (21). For each
scan of every image, this program identified the membrane
of the vesicle and fit the fluorescence intensity across the
membrane with a Gaussian function (see Supporting Mate-
rial). Solutions of purified fluorescent proteins were used to
calibrate the donor and acceptor fluorescence intensities as
described previously (25). The FRET efficiency, the donor
concentration, and the acceptor concentration were deter-
mined in each vesicle, as described inMaterials andMethods.In Fig. 2, we show the FRET efficiencies per vesicle
plotted against the acceptor concentration in that vesicle;
each data point corresponds to a single vesicle. Data for
the wild-type, Arg248Cys, Ser249Cys, and Tyr373Cys con-
structs are shown as open blue diamonds, red squares, green
triangles, and purple circles, respectively. Each data set con-
tains ~500þ single vesicles and was collected in more than
10 independent experiments. The solid black line in Fig. 2
indicates the expected FRET efficiency due to the random
approach of donors and acceptors (see (27) for details).
This proximity FRET contribution occurs because the fluo-
rophores are confined to the 2D membrane and has been
discussed in the literature (26,27,37). The data fall well
above this line, which indicates that the FRET we observe
is because of specific interactions between the receptors.
Furthermore, FRET efficiencies measured for the mutants
are higher than the efficiencies for the wild-type. Therefore,
the TDI mutations have an effect on FGFR3 dimerization.
FRET due to FGFR3 dimerization was determined by
correcting for proximity FRET (27). Then, we calculated
the product of the dimeric fraction in the vesicle, fD, and
the intrinsic FRET, Ẽ, using Eq. 8. To do so, we need the
donor and the acceptor concentrations in each vesicle,
which are measured as described in Materials and Methods
and are shown in Fig. 3. As discussed previously (21), theseBiophysical Journal 108(2) 272–278
TABLE 1 Dimerization constant, K, dimerization free energy,
DG, and intrinsic FRET, Ẽ, for the wild-type and mutants
Wild-type Arg248Cys Ser249Cys Tyr373Cys
K 2905 60 11105 130 5005 100 5905 110
Ẽ 0.515 0.04 0.745 0.03 0.735 0.03 0.625 0.03
DG0 (kcal/mol) 3.4 5 0.1 4.25 0.1 3.7 5 0.1 3.85 0.1
DDG0 (kcal/mol) 0.85 0.1 0.3 5 0.1 0.45 0.1
d (A˚) 53 5 1 455 1 45 5 1 495 1
The values of K and Ẽ are optimized in a two parameter fit of the FRET data
to a dimer model. Dimer stability is calculated as DG0¼ -RT ln K. The ef-
fect of the mutations on dimer stability,DDG0, is the difference between the
wild-type and mutant dimer stabilities. The distance between fluorescent
proteins, d, is calculated from Ẽ according to Eq. 7.
276 Del Piccolo et al.are 2D concentrations in the membrane. The dimerization
constant is a thermodynamic parameter that describes the
propensity for dimerization in quantitative terms. The
intrinsic FRET Ẽ is a structural parameter that is very sen-
sitive to changes in dimer structure, since FRET efficiency
falls off with the sixth power of distance between fluoro-
phores as seen in Eq. 7. The product of these two parame-
ters, fDẼ, is plotted in Fig. 4 as a function of the total
receptor concentration, after averaging the data in bins of
width 5  104 receptors/nm2.
Using c2 analysis (29), we performed a pairwise compar-
ison of the binned wild-type data set with each of the mutant
data sets. Reduced c2 values of 133.97, 55.33, and
28.91 were calculated for the Arg248Cys, Ser249Cys, and
Tyr373Cys mutants, respectively. The corresponding
p-values were all <0.001 and the observed differences
were highly statistically significant for all the mutants.
Since the experimental data in Fig. 4 depend on both the
dimerization constant, K, and the intrinsic FRET, Ẽ, we used
Eq. 8 and performed a two parameter fit on each data set to
determine the optimal K and Ẽ values for each construct.
The results of the fit are shown in Table 1, along with their
standard errors (67% confidence intervals). Next, the K and
Ẽ values were used to calculate additional characteristics
of the dimer; these results are also shown in Table 1. The
dimerization Gibbs free energy (dimer stability, DG0) was
calculated using the dimerization constant and Eq. 11. We
also calculated the effect of the mutations on dimer stability
(DDG0), given by the difference in dimer stability between a
given mutant and the wild-type. From the optimal intrinsic
FRET values, we calculated the distance between the
fluorescent proteins in each of the different FGFR3 dimers
using Eq. 7.
The dimeric fractions are shown in Fig. 5, along with the
binding curves corresponding to the optimal K values. The


























FIGURE 4 Dimeric fraction times intrinsic FRET, versus total receptor
concentration. These data are obtained from the FRET data in Fig. 2 using
Eq. 8, and are averaged within 5  104 receptors/nm2-wide concentration
bins. A reduced c2 analysis demonstrates that the mutant data sets are
significantly different from the wild-type data set. To see this figure in color,
go online.
Biophysical Journal 108(2) 272–278tors/nm2. A reduced c2 analysis demonstrated that the small
differences between the wild-type and the mutants are statis-
tically significant. The reduced c2 values are 36.03, 7.51,
and 8.35, such that the p-values are all <0.001. Further
statistical analysis, however, shows that the effects are
very modest, with the p-values from t-tests being 0.001,
0.15, and 0.006 for the Arg248Cys, Ser249Cys, and
Tyr373Cys mutants, respectively. By ANOVA, only the
effect of the Arg248Cys mutation is highly statistically
significant. Statistical analysis of the values of Ẽ yields
p-values of <0.001, <0.001, and 0.03 for the Arg248Cys,
Ser249Cys, and Tyr373Cys mutants, respectively. By
ANOVA, the effects of the Arg248Cys and Ser249Cys
mutations on intrinsic FRET, and thus structure, are highly
statistically significant.DISCUSSION
In FRET studies of RTK dimerization, the measured FRET
efficiencies depend on both RTK dimerization propensity
and RTK dimer structure (particularly on the distances be-






















FIGURE 5 Dimeric fraction versus total receptor concentration. Aver-
aged data are shown in 5  104 receptors/nm2-wide bins. The solid line
is the dimerization model, given by Eqs. 9 and 10, plotted for the optimized
dimerization constants in Table 1. A reduced c2 analysis demonstrates that
the differences between the mutant and wild-type dimeric fractions are
statistically significant. To see this figure in color, go online.
TDI Mutations and FGFR3 Dimerization 277this fact is sometimes not fully appreciated in FRET data
interpretation. In addition, the read-out of other experi-
mental techniques used in RTK research also depends
on both the dimerization propensity and on structural fac-
tors. For instance, receptor phosphorylation, measured in
Western blot experiments using anti-phospho-Tyrosine anti-
bodies, requires that the receptors are dimeric but also de-
pends on the exact positioning and orientation of the
kinase domains. The TDI mutations have been shown to in-
crease FGFR3 phosphorylation (7), as compared with wild-
type, but it is not known if the effect is because of increased
dimerization or structural perturbations that promote phos-
phorylation. Similarly, cross-linking efficiencies, measured
in Western blots using anti-receptor antibodies, depend
both on the fraction of dimeric receptors and on the presence
of suitable amine groups that are in close enough proximity
for cross-linking to occur. Thus, a change in cross-linking
because of a mutation may be because of either a change
in dimerization propensity or a change in structure, or both.
In this study, we characterized the ligand-independent
dimerization of three FGFR3 mutants linked to TDI in
plasma membrane-derived vesicles using a FRET-based
method. We overcome the limitations in data interpretation
by separating structural effects from dimerization effects.
This is accomplished by fitting a dimer model with two
adjustable parameters, the dimerization constant, K, and
the structural parameter intrinsic FRET, Ẽ, to the experi-
mental data.Modest changes in dimer stability because of the
TDI mutations in the absence of ligand
Dimerization constants report on the propensity for dimer
formation. For the wild-type receptor, we measured a dimer-
ization free energy of DG0 ¼ 3.4 5 0.1 kcal/mol, which
is consistent with previous FGFR3 experiments (22,23).
Concurrent experiments on the Arg248Cys, Ser249Cys,
and Tyr373Cys mutant constructs produced DG0 values
of 4.2 5 0.1, 3.7 5 0.1, and 3.8 5 0.1 kcal/mol,
respectively. Thus, the mutations have a modest effect on
dimer stability, confirmed by statistical analysis.
Literature values for the energetic contributions of disul-
fide bonds to protein interactions vary substantially, with
the most consensus lying around 2 to 4 kcal/mol
(38,39). Here, we measured that the Arg248Cys,
Ser249Cys, and Tyr373Cys mutations stabilize the FGFR3
dimer by 0.8, 0.3, and 0.4 kcal/mol, respectively.
These findings may suggest that disulfide bonds form with
low probability within the unliganded TDI dimers, most
likely because of structural constraints that make it difficult
for disulfide bonds to form. This means that, in our experi-
ments, we might probe two different mutant populations—
one consisting of a disulfide bonded dimer structure and
one consisting of a mutant dimer with a structure that is
practically the same as the wild-type—and that our mea-surements of K and Ẽ are average values, not molecular
characteristics of the disulfide bonded mutant dimers.Modest structural effects because of the TDI
mutations in the absence of ligand
Intrinsic FRET values report on the distances between
the fluorescent proteins in the dimer and are influenced by
the mobility of the fluorescent proteins. We show that the
Arg248Cys and Ser249Cys TDI mutations cause statisti-
cally significant effects on the intrinsic FRET, implying
that there are differences in the structures of the wild-type
and mutant dimers. Assuming free rotation of the fluores-
cent proteins, we calculate the average distance between
the fluorescent proteins in the wild-type dimer as 53 5
1 A˚, compared with 45 5 1 A˚, 45 5 1 A˚, and 49 5 1 A˚
for the Arg248Cys, Ser249Cys, and Tyr373Cys mutants,
respectively. Therefore, the fluorescent proteins are likely
closer to each other in the mutant dimers, suggesting a
decrease in the separation between the TM domains.Implications
Disulfide bonds in proteins or protein complexes are always
envisioned as very strong, because of their covalent nature.
Thus, one expects that disulfide bonds strongly stabilize pro-
tein folds and protein assemblies. In accordance with this
view, it is believed that the effects of pathogenic cysteine
mutations in RTKs are profound, with the disulfide bonds
inducing constitutive dimerization. Yet, actual experimental
measurements of disulfide bond-mediated stabilization for
soluble proteins and dimers point to rather modest effects,
on the order of 2 to 4 kcal/mole (38,39). In this study,
we present, to our knowledge, the first quantitative measure-
ment of the effect of cysteine mutations on membrane pro-
tein interactions. In particular, we study the TDI mutations
in FGFR3, which are linked to a lethal phenotype and are
thus expected to induce constitutive FGFR3 dimerization.
Surprisingly, we see modest effects on FGFR3 dimerization.
Furthermore, we see indications of structural perturbations
in the FGFR3 dimer due to the mutations. Thus, this study
does not support the simple view that the TDI cysteine mu-
tations cause pathologies by inducing constitutive FGFR3
dimerization.SUPPORTING MATERIAL
Fifty-two figures are available at http://www.biophysj.org/biophysj/
supplemental/S0006-3495(14)04673-6.ACKNOWLEDGMENTS
This work was supported by GM068619 and GM095930. We thank
Sarvenaz Sarabipour, Christopher King, Patrick Byrne, Dr. Daniel Leahy,
and Dr. Julia Koehler for useful discussions.Biophysical Journal 108(2) 272–278
278 Del Piccolo et al.REFERENCES
1. Cohen, Jr., M. M. 2006. The new bone biology: pathologic, molecular,
and clinical correlates. Am. J. Med. Genet. A. 140:2646–2706.
2. Cohen, Jr., M. M. 2002. Some chondrodysplasias with short limbs: mo-
lecular perspectives. Am. J. Med. Genet. 112:304–313.
3. Passos-Bueno, M. R., W. R. Wilcox,., H. Kitoh. 1999. Clinical spec-
trum of fibroblast growth factor receptor mutations. Hum. Mutat.
14:115–125.
4. Rousseau, F., V. el Ghouzzi, ., J. Bonaventure. 1996. Missense
FGFR3 mutations create cysteine residues in thanatophoric dwarfism
type I (TD1). Hum. Mol. Genet. 5:509–512.
5. L’Horte, C. G. M., and M. A. Knowles. 2005. Cell responses to FGFR3
signaling: growth, differentiation and apoptosis. Experim. Cell Res.
304:417–431.
6. Tavormina, P. L., R. Shiang, ., J. J. Wasmuth. 1995. Thanatophoric
dysplasia (types I and II) caused by distinct mutations in fibroblast
growth factor receptor 3. Nat. Genet. 9:321–328.
7. Adar, R., E. Monsonego-Ornan, ., A. Yayon. 2002. Differential
activation of cysteine-substitution mutants of fibroblast growth factor
receptor 3 is determined by cysteine localization. J. Bone Miner. Res.
17:860–868.
8. d’Avis, P. Y., S. C. Robertson,., D. J. Donoghue. 1998. Constitutive
activation of fibroblast growth factor receptor 3 by mutations respon-
sible for the lethal skeletal dysplasia thanatophoric dysplasia type I.
Cell Growth Differ. 9:71–78.
9. Krejci, P., L. Salazar,., W. R. Wilcox. 2008. Analysis of STAT1 acti-
vation by six FGFR3 mutants associated with skeletal dysplasia under-
mines dominant role of STAT1 in FGFR3 signaling in cartilage. PLoS
ONE. 3:e3961. http://dx.doi.org/10.1371/journal.pone.0003961.
10. Naski, M. C., Q. Wang, ., D. M. Ornitz. 1996. Graded activation of
fibroblast growth factor receptor 3 by mutations causing achondro-
plasia and thanatophoric dysplasia. Nat. Genet. 13:233–237.
11. Bonaventure, J., W. C. Horne, and R. Baron. 2007. The localization of
FGFR3 mutations causing thanatophoric dysplasia type I differentially
affects phosphorylation, processing and ubiquitylation of the receptor.
FEBS J. 274:3078–3093.
12. Harada, D., Y. Yamanaka,., Y. Seino. 2009. FGFR3-related dwarfism
and cell signaling. J. Bone Miner. Metab. 27:9–15.
13. Deng, C., A. Wynshaw-Boris, ., P. Leder. 1996. Fibroblast growth
factor receptor 3 is a negative regulator of bone growth. Cell.
84:911–921.
14. Foldynova-Trantirkova, S., W. R. Wilcox, and P. Krejci. 2012. Sixteen
years and counting: the current understanding of fibroblast growth fac-
tor receptor 3 (FGFR3) signaling in skeletal dysplasias. Hum. Mutat.
33:29–41.
15. Goetz, R., and M. Mohammadi. 2013. Exploring mechanisms of FGF
signalling through the lens of structural biology. Nat. Rev. Mol. Cell
Biol. 14:166–180.
16. Ornitz, D. M. 2000. FGFs, heparan sulfate and FGFRs: complex inter-
actions essential for development. BioEssays. 22:108–112.
17. Ornitz, D. M., and N. Itoh. 2001. Fibroblast growth factors. Genome
Biol. 2:3005.
18. Greulich, H., B. Kaplan,., M. Meyerson. 2012. Functional analysis of
receptor tyrosine kinase mutations in lung cancer identifies oncogenic
extracellular domain mutations of ERBB2. Proc. Natl. Acad. Sci. USA.
109:14476–14481.
19. Phay, J. E., and M. H. Shah. 2010. Targeting RET receptor tyrosine
kinase activation in cancer. Clin. Cancer Res. 16:5936–5941.Biophysical Journal 108(2) 272–27820. Iyer, G., and M. I. Milowsky. 2013. Fibroblast growth factor receptor-3
in urothelial tumorigenesis. Urol. Oncol. 31:303–311.
21. Chen, L., L. Novicky,., K. Hristova. 2010. Measuring the energetics
of membrane protein dimerization in mammalian membranes. J. Am.
Chem. Soc. 132:3628–3635.
22. Chen, L., J. Placone, ., K. Hristova. 2010. The extracellular domain
of fibroblast growth factor receptor 3 inhibits ligand-independent
dimerization. Sci. Signal. 3:ra86.
23. Del Piccolo, N., J. Placone, ., K. Hristova. 2012. Production of
plasma membrane vesicles with chloride salts and their utility as a
cell membrane mimetic for biophysical characterization of membrane
protein interactions. Anal. Chem. 84:8650–8655.
24. Sarabipour, S., C. King, and K. Hristova. 2014. Uninduced high-
yield bacterial expression of fluorescent proteins. Anal. Biochem.
449:155–157.
25. Li, E., J. Placone,., K. Hristova. 2008. Quantitative measurements of
protein interactions in a crowded cellular environment. Anal. Chem.
80:5976–5985.
26. Wolber, P. K., and B. S. Hudson. 1979. An analytic solution to the
Fo¨rster energy transfer problem in two dimensions. Biophys. J.
28:197–210.
27. King, C., S. Sarabipour,., K. Hristova. 2014. The FRET signatures of
noninteracting proteins in membranes: simulations and experiments.
Biophys. J. 106:1309–1317.
28. Evers, T. H., E. M. W. M. van Dongen,., M. Merkx. 2006. Quantita-
tive understanding of the energy transfer between fluorescent proteins
connected via flexible peptide linkers. Biochemistry. 45:13183–13192.
29. Bevington, P. R. 1969. Data reduction and error analysis for the phys-
ical sciences. McGraw-Hill Book Company, New York.
30. Scott, R. E. 1976. Plasma membrane vesiculation: a new technique for
isolation of plasma membranes. Science. 194:743–745.
31. Scott, R. E., and P. B. Maercklein. 1979. Plasma membrane vesicula-
tion in 3T3 and SV3T3 cells. II. Factors affecting the process of vesic-
ulation. J. Cell Sci. 35:245–252.
32. Scott, R. E., R. G. Perkins, ., P. B. Maercklein. 1979. Plasma
membrane vesiculation in 3T3 and SV3T3 cells. I. Morphological
and biochemical characterization. J. Cell Sci. 35:229–243.
33. Placone, J., and K. Hristova. 2012. Direct assessment of the effect of
the Gly380Arg achondroplasia mutation on FGFR3 dimerization using
quantitative imaging FRET. PLoS ONE. 7:e46678.
34. Placone, J., L. He,., K. Hristova. 2014. Strong dimerization of wild-
type ErbB2/Neu transmembrane domain and the oncogenic Val664Glu
mutant in mammalian plasma membranes. Biochim. Biophys. Acta.
1838:2326–2330.
35. Sarabipour, S., and K. Hristova. 2013. Glycophorin A transmembrane
domain dimerization in plasma membrane vesicles derived from CHO,
HEK 293T, and A431 cells. Biochim. Biophys. Acta. 1828:1829–1833.
36. Sarabipour, S., and K. Hristova. 2013. FGFR3 transmembrane domain
interactions persist in the presence of its extracellular domain.
Biophys. J. 105:165–171.
37. Freire, E., and B. Snyder. 1982. Quantitative characterization of the
lateral distribution of membrane proteins within the lipid bilayer.
Biophys. J. 37:617–624.
38. Betz, S. F. 1993. Disulfide bonds and the stability of globular proteins.
Protein Sci. 2:1551–1558.
39. McAuley, A., J. Jacob, ., M. Matsumura. 2008. Contributions of a
disulfide bond to the structure, stability, and dimerization of human
IgG1 antibody CH3 domain. Protein Sci. 17:95–106.
